Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: Experience with 1162 patients

Journal of Rheumatology

Volumn 41, Issue 12, 2014, Pages 2395-2402

  Payet, Judith ^a   Goulvestre, Claire ^a   Bialé, Lisa ^a   Avouac, Jérôme ^a   Wipff, Julien ^a   Job Deslandre, Chantal ^a   Batteux, Frédéric ^a   Dougados, Maxime ^a   Kahan, André ^a   Allanore, Yannick ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Anticyclic citrullinated peptide antibodies; Diagnosis; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ANTIIDIOTYPIC ANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; DESCRIPTIVE RESEARCH; DIAGNOSTIC VALUE; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; OBSERVATIONAL STUDY; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; AGED; ARTHRITIS, JUVENILE; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BLOOD; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RETROSPECTIVE STUDY; RHEUMATIC DISEASES; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; SJOGREN'S SYNDROME;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, JUVENILE; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; SJOGREN'S SYNDROME;

EID: 84915826536     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131375     Document Type: Article

References (51)

1. Aggarwal R, Liao K, Nair R, Ringlod S, Costenbader KH. Anti-citrullinated peptide antibody (ACPA) assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum 2009;61:1472-83.
2. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006;65:453-8.
3. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64:1744-9.
4. Van der Linden MP, Van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, et al. Value of antimodified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared to second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009;60:2232-41.
5. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
6. Burr ML, Viatte S, Bukhari M, Plant D, Symmons DP, Thomson W, et al. Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis. Arthritis Res Ther 2012;14:R109.
7. Miriovsky BJ, Michaud K, Thiele GM, O'Dell JR, Cannon GW, Kerr G, et al. Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis 2010;69:1292-7.
8. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006;65:845-51.
9. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
10. Fabien N, Olsson NO, Goetz J, Johanet C, Escande A, Bardin N, et al. Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study. Clin Rev Allergy Immunol 2008;34:40-4.
11. Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D, et al. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 2004;135:173-80.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
14. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
15. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR study group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
16. Faith A, Pontesilli O, Unger A, Panayi GS, Johns P. ELISA assays for IgM and IgG rheumatoid factors. J Immunol Methods 1982;55:169-77.
17. Abdel Fattah NS, Hassan HE, Galal ZA, El Okda SE. Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis. BMC Res Notes 2009;2:44.
18. Maejima H, Aki R, Watarai A, Shirai K, Hamada Y, Katsuoka K. Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patients. J Dermatol 2010;37:339-45.
19. Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H, et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007;26:17-23.
20. Korendowych E, Owen P, Ravindran J, Carmichael C, McHugh N. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology 2005;44:1056-60.
21. Bogliolo L, Alpini C, Caporali R, Scirè CA, Moratti R, Montecucco C. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. Rheumatol 2005;32:511-5.
22. Atzeni F, Sarzi-Puttini P, Lama N, Bonacci E, Bobbio-Pallavicini F, Montecucco C, et al. Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 2008;10:51-8.
23. Gottenberg JE, Mignot S, Nicaise-Rolland P, Cohen-Solal J, Aucouturier F, Goetz J, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis 2005;64:114-7.
24. Taraborelli M, Inverardi F, Fredi M, Ceribelli A, Cavazzana I, Tincani A, et al. Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease? Reumatismo 2012;64:321-5.
25. Chan MT, Owen P, Dunphy J, Cox B, Carmichael C, Korendowych E, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC class II alleles in systemic lupus erythematosus. J Rheumatol 2008;35:77-83.
26. Amezcua-Guerra LM, Springall R, Marquez-Velasco R, Gomez-Garcia L, Vargas A, Bojalil R. Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study. Arthritis Res Ther 2006;8:R144.
27. Kakumanu P, Sobel ES, Narain S, Li Y, Akaogi J, Yamasaki Y, et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol 2009;36:2682-90.
28. Zhao Y, Li J, Li XX, Li C, Li L, Li ZG. What can we learn from the presence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus? Joint Bone Spine 2009;76:501-7.
29. Avouac J, Mogavero G, Guerini H, Drapé JL, Mathieu A, Allanore Y. Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study. Ann Rheum Dis 2011;70:630-3.
30. Qing YF, Zhang QB, Zhou JG, Yuan GH, Wei J, Xing Y, et al. The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus. Lupus 2009;18:713-7.
31. Takasaki Y, Yamanaka K, Takasaki C, Matsushita M, Yamada H, Nawata M, et al. Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol 2004;14:367-75.
32. Haga HJ, Andersen DT, Peen E. Prevalence of IgA class antibodies to cyclic citrullinated peptide (anti-CCP) in patients with primary Sjögren's syndrome, and its association to clinical manifestations. Clin Rheumatol 2011;30:369-72.
33. Viana VS, de Carvalho JF, de Moraes JC, Saad CG, Ribeiro AC, Gonc¸alves C, et al. Autoantibodies in patients with psoriatic arthritis on anti-TNFα therapy. Rev Bras Reumatol 2010;50:225-34.
34. Shibata S, Tada Y, Komine M, Hattori N, Osame S, Kanda N, et al. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis. J Dermatol Sci 2009;53:34-9.
35. Pasquetti P, Morozzi G, Galeazzi M. Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis. Rheumatology 2009;48:315-6.
36. Tesija-Kuna A, Grazio S, Miler M, Vukasovic I, Peric P, Vrkic N. Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis. Clin Rheumatol 2010;29:487-93.
37. Ueda-Hayakawa I, Hasegawa M, Kumada S, Tanaka C, Komura K, Hamaguchi Y, et al. Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology 2010;49:2135-9.
38. Polimeni M, Feniman D, Skare TS, Nisihara RM. Anti-cyclic citrullinated peptide antibodies in scleroderma patients. Clin Rheumatol 2012;31:877-80.
39. Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S, et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP-3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008;27:77-83.
40. Moryta Y, Muro K, Sugiura K, Tomita Y. Anti citrullinated peptide antibody in systemic sclerosis. Clin Exp Rheumatol 2008;26:542-7.
41. Singh U, Singh S, Singh NK, Verma PK, Singh S. Anticyclic citrullinated peptide autoantibodies in systemic lupus erythematosus. Rheumatol Int 2011;31:765-7.
42. Mediwake M, Isenberg DA, Schellekens GA, van Venrooij WJ. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2001;60:67-8.
43. Martinez JB, Valero JS, Bautista AJ, Restrepo JF, Matteson EL, Rondon F, et al. Erosive arthropathy: clinical variance in lupus erythematosus and association with anti-CCP case series and review of the literature. Clin Exp Rheumatol 2007;25:47-53.
44. Tebo AE, Jaskowski T, Davis KW, Whiting A, Clifford B, Zeft A, et al. Profiling anti-cycling citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2012;10:29.
45. Gupta R, Thabah MM, Vaidya B, Gupta S, Lodha R, Kabra SK. Anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Indian J Pediatr 2010;77:41-4.
46. Skare TS, Nisihara RM, Silva RM, Munhoz da Silva DJ, Gameiro Silva MB, Utiyama SR. Anti-cyclic citrullinated peptide antibodies in adult patients with juvenile idiopathic arthritis. J Clin Rheumatol 2011;17:421-3.
47. Omar A, Abo-Elyoun I, Hussein H, Nabih M, Atwa H, Gad S, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): correlations with disease activity and severity of joint damage (a multicenter trial). Joint Bone Spine 2013;80:38-43.
48. Habib HM, Mosaad YM, Youssef HM. Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Immunol Invest 2008;37:849-57.
49. Kamali S, Polat NG, Kasapoglu E, Gul A, Ocal L, Aral O, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren's syndrome, and Wegener's granulomatosis. Clin Rheumatol 2005;24:673-6.
50. Pietrapertosa D, Tolusso B, Gremese E, Papalia MC, Bosello SL, Peluso G, et al. Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios. Clin Chem Lab Med 2010;48:829-34.
51. Kim DA, Kim TY. Is serum anti-cyclic citrullinated peptide level useful in the diagnosis of rheumatoid arthritis? Clin Chim Acta 2010;413:831-2.